Tissue Analysis After Tumor Ablation for Liver Metastases

This study is looking at whether analyzing tissue samples from liver metastases (cancer that has spread to the liver) after a tumor ablation procedure can find any remaining living cancer cells. You might be eligible if you have liver metastases from various primary tumors, your liver disease is confined or your extrahepatic (outside the liver) disease is stable, and your lesions are 3 cm or smaller. The study involves diagnostic tests like [18-F]- FDG - PET scans and PET/CT Scans, and a tumor ablation procedure. The main goal is to see how your tumor responds over 2 years. The study is currently unclear on its recruitment status and plans to enroll 200 participants.

Study design: This is an interventional study planning to enroll 200 participants. It is not specified if it is randomized or blinded.
What's involved: You would undergo [18-F]- FDG - PET scans, a tumor ablation procedure, and PET/CT scans within approximately 6 weeks (+/- 2 weeks) of tumor ablation.
Compensation: Not stated in the trial record.
Follow-up: Your tumor response will be measured at 2 years after the intervention.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

Tissue Analysis After Tumor Ablation for Liver Metastases Leading to Immediate Retreatment

Recruiting

PHASE2Ages 18+InterventionalDiagnostic

Memorial Sloan Kettering Cancer Center

~200 participants

Updated 2026-03-19 on ClinicalTrials.gov

What's tested:[18-F]- FDG - PETTumor ablation (TA)PET/CT Scan

At a glance

Recruiting sites

1 of 1 listed site is recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Tumor response

Measured over 2 years

Conditions

Liver Metastases

NCT04143516

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

Memorial Sloan Kettering Cancer Center
New York, New Yorkstudy coordinator listed
Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

Constantinos Sofocleous, MD, PhD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center

Who to contact

Constantinos Sofocleous, MD, PhD

[email protected]

212-639-3379

Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

Diagnosis of liver metastases from various primary tumors

Confined liver disease or limited extrahepatic disease stable/controlled for at least 4 months (extrahepatic disease amenable to treatment is allowed)

Lesions of ≤3 cm in maximum diameter

At least one FDG-avid lesion to be treated\*\*\*

INR \< 1.5\*

Platelet count ≥ 50,000

Exclusion

Age \< 18

Less than 5 mm distance to a structure (GI or biliary tract), that cannot be protected from ablation injury with technical modifications such as hydro or air dissection

INR \> 1.5 that cannot be corrected with fresh frozen plasma \*\*

Platelet count of \<50,000 that cannot be corrected with transfusion

More than 3 tumors in the liver

More than 5 tumors of extrahepatic disease (including mediastinal nodes and pulmonary nodules, abdominal or other lymph nodes, and bone metastasis)

Presence of any peritoneal Carcinomatosis

For patients on Coumadin, general clinical guidelines for IR ablation will be followed.

For patients with no FDG-PET avid tumors aim 2 of the protocol will not be assessed

What this trial measures

Tumor response2 years
will be measured according to RECIST and PERCIST 1.0. The first CT and PET scan taken after ablation will be considered the new baseline for subsequent comparisons and measurements.

Trialytics